ViiV Healthcare's Vocabria in Combination with Rekambys Receives the NMPA’s Approval as an HIV-1 Injectable Treatment
Shots:
- The approval was based on the data from the (ATLAS), (FLAIR) & P-IIIb (ATLAS-2M) clinical trials evaluating the safety & efficacy of Vocabria (cabotegravir) + Rekambys (rilpivirine) vs SoC in patients (n=1,200) with HIV-1 infection
- The results from the (ATLAS) & (FLAIR) trials showed that 92.5% & 93.6% of patients receiving long-acting injectables remained virally suppressed vs 95.5% & 93.3% of those receiving oral therapy. In the P-IIIb (ATLAS-2M) trial, patients (n=1,045) receiving the long-acting therapy Q8W were non-inferior to dosing at Q4W post 48wks. of treatment
- Vocabria (cabotegravir) is an integrase strand transfer inhibitor that inhibits the replication of HIV by preventing the viral DNA from integrating into the genetic material of T-cells
Ref: GSK | Image: ViiV Healthcare
Related News:- ViiV's Vocabria (cabotegravir- tablet formulation) Receives the US FDA's Approval for the Treatment of HIV-1 infection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
